Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Pharmacokinetics and Pharmacodynamics"
DOI: 10.1007/s10928-018-9592-y
Abstract: Evolocumab, a novel human monoclonal antibody, inhibits proprotein convertase subtilisin/kexin type 9, a protein that targets low-density lipoprotein-cholesterol (LDL-C) receptors for the treatment of hyperlipidemia. The primary objective of this analysis was to characterize the… read more here.
Keywords: exposure response; response; population pharmacokinetics; simulation ... See more keywords